Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379677 | 1.00 | PPARG (0.46) | PPARGPPARDPPARAMEN1ALDH1A1 | |
| SCHEMBL29381267 | 0.89 | PPARG (0.44) | PPARGPPARDPPARAMEN1ALDH1A1 | |
| SCHEMBL498905 | 0.89 | PPARG (0.44) | PPARGPPARDPPARAMEN1ALDH1A1 | |
| SCHEMBL498631 | 0.88 | CA1 (0.42) | MEN1ALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL499469 | 0.88 | MAPT (0.40) | MAPTGAALMNAKDM4EHPGD | |
| SCHEMBL498671 | 0.87 | PPARG (0.47) | PPARGPPARDPPARAMEN1ALDH1A1 | |
| SCHEMBL29386613 | 0.87 | PPARG (0.47) | PPARGPPARDPPARAMEN1ALDH1A1 | |
| SCHEMBL15361865 | 0.86 | CYP1A1 (0.49) | MAOB | |
| SCHEMBL29381917 | 0.86 | CYP1A1 (0.49) | MAOB | |
| SCHEMBL29214716 | 0.86 | CYP1A1 (0.37) | MEN1MAPTKMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350341-B1 | METHODS FOR DIAGNOSING AND EVALUATING NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2021-08-11 | — | — | EP | claimed |
| EP-3712279-A1 | METHODS FOR DIAGNOSING AND EVALUATING NON-ALCOHOLIC STEATOHEPATITIS | Genfit (FR) | 2020-09-23 | — | — | EP | claimed |
| US-20200248261-A1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC FATTY LIVER DISEASES, NON-ALCOHOLIC STEATOHEPATITIS AND/OR LIVER FIBROSIS | GENFIT (FR) | 2020-08-06 | — | — | US | claimed |
| US-20200216901-A1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC FATTY LIVER DISEASES, NON-ALCOHOLIC STEATOHEPATITIS AND/OR LIVER FIBROSIS | GENFIT (FR) | 2020-07-09 | — | — | US | claimed |
| US-20180265924-A1 | METHODS FOR DIAGNOSING AND EVALUATING NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2018-09-20 | — | — | US | claimed |
| EP-2641596-B1 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2018-05-02 | — | — | EP | claimed |
| US-20160051501-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2016-02-25 | — | — | US | claimed |
| US-20150051145-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2015-02-19 | — | — | US | claimed |
| EP-2504005-B1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2013-11-06 | — | — | EP | claimed |
| US-8461212-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2013-06-11 | — | — | US | claimed |
| US-20120252725-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2012-10-04 | — | — | US | claimed |
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2012-05-24 | — | — | US | claimed |
| US-7943661-B2 | Antiischemic agents; for example 1-[2-hydroxy-4-chlorophenyl]-3-[4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one; display peroxisome proliferator activated receptor (PPAR) activator, antioxidant and antiinflammatory properties | GENFIT (FR) | 2011-05-17 | — | — | US | claimed |
| US-7632870-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2009-12-15 | — | — | US | claimed |
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | claimed |
| EP-1525177-B1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2007-06-27 | — | — | EP | claimed |
| EP-1519908-B1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2007-06-13 | — | — | EP | claimed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | claimed |
| US-20050171149-A1 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2005-08-04 | — | — | US | claimed |
| US-12458612-B2 | Combination therapy comprising compounds of formula (I) and GLP-1 receptor agonists | GENFIT (FR) | 2025-11-04 | — | — | US | disclosed |
| US-12208087-B2 | Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation | GENFIT (FR) | 2025-01-28 | — | — | US | disclosed |
| US-11974997-B2 | RORgamma modulators and uses thereof | GENFIT (FR) | 2024-05-07 | — | — | US | disclosed |
| US-11590108-B2 | Pharmaceutical compositions for combination therapy | GENFIT (FR) | 2023-02-28 | — | — | US | disclosed |
| US-11519034-B2 | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis | GENFIT (FR) | 2022-12-06 | — | — | US | disclosed |
| US-20220362187-A1 | COMBINATION THERAPY COMPRISING COMPOUNDS OF FORMULA (I) AND GLP-1 RECEPTOR AGONISTS | GENFIT (FR) | 2022-11-17 | — | — | US | disclosed |
| US-11371098-B2 | Methods for diagnosing and evaluating non-alcoholic steatohepatitis | GENFIT (FR) | 2022-06-28 | — | — | US | disclosed |
| US-20220175737-A1 | COMBINATION OF NITAZOXANIDE AND ELAFIBRANOR FOR THE TREATMENT OF IMMUNE DISEASES OR INFLAMMATION | GENFIT (FR) | 2022-06-09 | — | — | US | disclosed |
| US-20220162702-A1 | DIAGNOSIS OF NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2022-05-26 | — | — | US | disclosed |
| EP-3952855-A1 | COMBINATION THERAPY COMPRISING COMPOUNDS OF FORMULA (I) AND GLP-1 RECEPTOR AGONISTS | Genfit (FR) | 2022-02-16 | — | — | EP | disclosed |
| US-11160801-B2 | RORgamma modulators and uses thereof | GENFIT (FR) | 2021-11-02 | — | — | US | disclosed |
| US-20210275504-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | GENFIT (FR) | 2021-09-09 | — | — | US | disclosed |
| US-11077115-B2 | Rorgamma modulators and uses thereof | GENFIT (FR) | 2021-08-03 | — | — | US | disclosed |
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | GENFIT (FR) | 2021-07-06 | — | — | US | disclosed |
| US-20200384105-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2020-12-10 | — | — | US | disclosed |
| WO-2020208205-A1 | COMBINATION THERAPY COMPRISING COMPOUNDS OF FORMULA (I) AND GLP-1 RECEPTOR AGONISTS | GENFIT (FR) | 2020-10-15 | — | — | WO | disclosed |
| US-10722575-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2020-07-28 | — | — | US | disclosed |
| US-20200216901-A1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC FATTY LIVER DISEASES, NON-ALCOHOLIC STEATOHEPATITIS AND/OR LIVER FIBROSIS | GENFIT (FR) | 2020-07-09 | — | — | US | disclosed |
| US-20200206169-A1 | COMBINATION COMPRISING A PPAR AGONIST SUCH AS ELAFIBRANOR AND AN ACETYL-COA CARBOXYLASE (ACC) INHIBITOR | GENFIT (FR) | 2020-07-02 | — | — | US | disclosed |
| US-20200121625-A1 | COMBINATION OF ELAFIBRANOR OR DERIVATIVES THEREOF WITH AN ANTI-NASH, ANTI-FIBROTIC OR ANTI-CHOLESTATIC AGENT | GENFIT (FR) | 2020-04-23 | — | — | US | disclosed |
| US-20200054589-A1 | COMBINATION OF A PPAR AGONIST WITH A FXR AGONIST | GENFIT (FR) | 2020-02-20 | — | — | US | disclosed |
| US-20190352715-A1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2019-11-21 | — | — | US | disclosed |
| US-20190275146-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2019-09-12 | — | — | US | disclosed |
| US-10350181-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2019-07-16 | — | — | US | disclosed |
| US-20180280328-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2018-10-04 | — | — | US | disclosed |
| US-20180265924-A1 | METHODS FOR DIAGNOSING AND EVALUATING NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2018-09-20 | — | — | US | disclosed |
| US-10022343-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2018-07-17 | — | — | US | disclosed |
| US-20170368007-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2017-12-28 | — | — | US | disclosed |
| US-9782373-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2017-10-10 | — | — | US | disclosed |
| US-20170128399-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2017-05-11 | — | — | US | disclosed |
| US-9585853-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2017-03-07 | — | — | US | disclosed |
| US-20160051501-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2016-02-25 | — | — | US | disclosed |
| US-9221751-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2015-12-29 | — | — | US | disclosed |
| US-20150051145-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2015-02-19 | — | — | US | disclosed |
| US-8895619-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2014-11-25 | — | — | US | disclosed |
| US-20140309165-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2014-10-16 | — | — | US | disclosed |
| US-8772342-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2014-07-08 | — | — | US | disclosed |
| US-8461212-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2013-06-11 | — | — | US | disclosed |
| EP-2571843-A1 | IMPROVED PREPARATION OF CHALCONE DERIVATIVES | Genfit (FR) | 2013-03-27 | — | — | EP | disclosed |
| US-20120252725-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2012-10-04 | — | — | US | disclosed |
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2012-05-24 | — | — | US | disclosed |
| US-8106097-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2012-01-31 | — | — | US | disclosed |
| WO-2011144579-A1 | IMPROVED PREPARATION OF CHALCONE DERIVATIVES | GENFIT (FR) | 2011-11-24 | — | — | WO | disclosed |
| US-8058308-B2 | Substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2011-11-15 | — | — | US | disclosed |
| US-20110190515-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2011-08-04 | — | — | US | disclosed |
| US-7943661-B2 | Antiischemic agents; for example 1-[2-hydroxy-4-chlorophenyl]-3-[4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one; display peroxisome proliferator activated receptor (PPAR) activator, antioxidant and antiinflammatory properties | GENFIT (FR) | 2011-05-17 | — | — | US | disclosed |
| US-20100120909-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2010-05-13 | — | — | US | disclosed |
| US-7632870-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2009-12-15 | — | — | US | disclosed |
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | disclosed |
| US-7385082-B2 | Preparation of 1,3-diphenylprop-2-en-1-one derivatives | GENFIT (FR) | 2008-06-10 | — | — | US | disclosed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | disclosed |
| US-20060142611-A1 | Preparation of 1,3-diphenylprop-2-en-1-one derivatives | GENFIT (FR) | 2006-06-29 | — | — | US | disclosed |
| US-20050176808-A1 | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | GENFIT (FR) | 2005-08-11 | — | — | US | disclosed |
| US-20050171149-A1 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2005-08-04 | — | — | US | disclosed |
| US-20050171149-A1 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (37 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054589-A1 | COMBINATION OF A PPAR AGONIST WITH A FXR AGONIST | NR1H4, PPARG, PPARD | PPARG 2/4885PPARD 3/4885PPARA 4/4885 |
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | RORA, RORC, RORB | PPARG 10/4885PPARD 29/4885PPARA 24/4885 |
| US-20220175737-A1 | COMBINATION OF NITAZOXANIDE AND ELAFIBRANOR FOR THE TREATMENT OF IMMUNE DISEASES OR INFLAMMATION | PPARD, PPARA, PPARG | PPARG 3/4885PPARD 1/4885PPARA 2/4885 |
| US-20140309165-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT1, GOT2 | PPARG 315/4885PPARD 349/4885PPARA 251/4885 |
| US-20170368007-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | PPARG 119/4885PPARD 94/4885PPARA 65/4885 |
| US-20170128399-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | PPARG 119/4885PPARD 94/4885PPARA 65/4885 |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | PSEN1, BACE1, PSEN2 | PPARG 17/4885PPARD 39/4885PPARA 69/4885 |
| US-20190352715-A1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS | FABP1, SLC10A1, FABP2 | PPARG 381/4885PPARD 350/4885PPARA 391/4885 |
| US-20160051501-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | PPARG 119/4885PPARD 94/4885PPARA 65/4885 |
| US-20150051145-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | PPARG 119/4885PPARD 94/4885PPARA 65/4885 |
| US-11590108-B2 | Pharmaceutical compositions for combination therapy | PCSK9, SLC10A1, PCSK7 | PPARG 280/4885PPARD 1082/4885PPARA 867/4885 |
| US-20190275146-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | PPARG 119/4885PPARD 94/4885PPARA 65/4885 |
| US-20210275504-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | PCSK9, SLC10A1, HMGCR | PPARG 531/4885PPARD 1205/4885PPARA 974/4885 |
| US-11974997-B2 | RORgamma modulators and uses thereof | RORB, RORC, RORA | PPARG 37/4885PPARD 61/4885PPARA 71/4885 |
| US-12458612-B2 | Combination therapy comprising compounds of formula (I) and GLP-1 receptor agonists | GLP1R, GIPR, GCGR | PPARG 6/4885PPARD 11/4885PPARA 10/4885 |
| US-12208087-B2 | Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation | PPARD, PPARA, PPARG | PPARG 3/4885PPARD 1/4885PPARA 2/4885 |
| US-20110190515-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | PGF, PTGS1, PTGES3 | PPARG 89/4885PPARD 120/4885PPARA 136/4885 |
| US-20100120909-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | BRCA1, COL1A1, APOL1 | PPARG 119/4885PPARD 193/4885PPARA 112/4885 |
| US-20180280328-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | PPARG 119/4885PPARD 94/4885PPARA 65/4885 |
| US-20180265924-A1 | METHODS FOR DIAGNOSING AND EVALUATING NON-ALCOHOLIC STEATOHEPATITIS | APOB, IL33, IL36G | PPARG 732/4885PPARD 1070/4885PPARA 1323/4885 |
| US-11371098-B2 | Methods for diagnosing and evaluating non-alcoholic steatohepatitis | APOB, IL33, IL36G | PPARG 732/4885PPARD 1070/4885PPARA 1323/4885 |
| US-20200206169-A1 | COMBINATION COMPRISING A PPAR AGONIST SUCH AS ELAFIBRANOR AND AN ACETYL-COA CARBOXYLASE (ACC) INHIBITOR | ACACA, PPARA, PPARG | PPARG 3/4885PPARD 5/4885PPARA 2/4885 |
| US-20200384105-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | PPARG 119/4885PPARD 94/4885PPARA 65/4885 |
| US-10722575-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | FABP1, GOT2, GOT1 | PPARG 119/4885PPARD 94/4885PPARA 65/4885 |
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | BRCA1, COL1A1, APOL1 | PPARG 119/4885PPARD 193/4885PPARA 112/4885 |
| US-10350181-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | FABP1, GOT2, GOT1 | PPARG 119/4885PPARD 94/4885PPARA 65/4885 |
| US-20220162702-A1 | DIAGNOSIS OF NON-ALCOHOLIC STEATOHEPATITIS | FABP1, SLC10A1, FABP2 | PPARG 168/4885PPARD 120/4885PPARA 144/4885 |
| US-20200121625-A1 | COMBINATION OF ELAFIBRANOR OR DERIVATIVES THEREOF WITH AN ANTI-NASH, ANTI-FIBROTIC OR ANTI-CHOLESTATIC AGENT | FABP1, HDGF, HGF | PPARG 39/4885PPARD 46/4885PPARA 22/4885 |
| US-20050176808-A1 | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | PGF, PTGS1, PTGES3 | PPARG 80/4885PPARD 111/4885PPARA 124/4885 |
| US-20220362187-A1 | COMBINATION THERAPY COMPRISING COMPOUNDS OF FORMULA (I) AND GLP-1 RECEPTOR AGONISTS | GLP1R, GIPR, GPR119 | PPARG 5/4885PPARD 7/4885PPARA 8/4885 |
| US-20050171149-A1 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | BRCA1, LOXL1, APOL1 | PPARG 88/4885PPARD 149/4885PPARA 81/4885 |
| US-11160801-B2 | RORgamma modulators and uses thereof | RORB, RORC, RORA | PPARG 37/4885PPARD 61/4885PPARA 71/4885 |
| US-20120252725-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT1, GOT2 | PPARG 315/4885PPARD 349/4885PPARA 251/4885 |
| US-20060142611-A1 | Preparation of 1,3-diphenylprop-2-en-1-one derivatives | DPEP1, PKD1, ENPP1 | PPARG 1047/4885PPARD 297/4885PPARA 275/4885 |
| US-10022343-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | FABP1, GOT2, GOT1 | PPARG 119/4885PPARD 94/4885PPARA 65/4885 |
| US-11077115-B2 | Rorgamma modulators and uses thereof | RORB, RORC, RORA | PPARG 41/4885PPARD 92/4885PPARA 99/4885 |
| US-20200248261-A1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC FATTY LIVER DISEASES, NON-ALCOHOLIC STEATOHEPATITIS AND/OR LIVER FIBROSIS | FABP1, FABP2, SLC10A1 | PPARG 723/4885PPARD 381/4885PPARA 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.